Apricus in-licenses US rights to ED drug from Allergan

10 September 2015

Shares of USA-based Apricus Biosciences (Nasdaq: APRI) gained 10.4% to $1.88 in early trading, as the company revealed it has licensed the US development and commercialization rights for Vitaros (alprostadil) from Allergan (NYSE: ACT).

Under the agreement, Apricus will be responsible for all Vitaros development efforts in the USA. Upon the Food and Drug Administration's acceptance of a New Drug Application for Vitaros, Allergan may elect to exercise its one time opt-in right to assume all future marketing and selling activities in the USA in exchange for certain financial considerations.

Vitaros is a novel, on-demand topical cream for the treatment of erectile dysfunction (ED) and a new potential entrant into the US ED treatment market. In February 2009, Warner Chilcott, now a subsidiary of Allergan, acquired the US rights to Vitaros from Apricus. Since that time, Vitaros has been approved by the European health authorities and by Health Canada, and is currently being promoted by Apricus' licensees throughout Europe.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK